Aggressive treatment of dyslipidemia: A review of supporting evidence

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 2, 2001, Pages 130-142

  Stein, Evan A ^a,b  

^a Pharmaceutical Product Development   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MORTALITY; REVIEW; SMOKING; VASCULAR ENDOTHELIUM;

EID: 0035111813     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.2.130     Document Type: Review

References (58)

1. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823-2828.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257:2176-2180.
3. Abbott RD, Wilson PW, Kannel WB, Castelli WR High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8:207-211.
4. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70:733-737.
5. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77:1179-1184.
6. Jeppesen J, Hein HO, Suadicani R Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17:1114-1120.
7. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70:3H-9H.
8. Castelli WP. Lipids, risk factors and ischemic heart disease. Atherosclerosis 1996; 124(Suppl):S1-S9.
9. Dangas G, Mehran R, Harpel PC, Sharma SK, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32:2035-2042.
10. Badimon JJ, Fuster V, Chesebro JH, Badimon L Coronary atherosclerosis, multifactorial disease. Circulation 1993; 87(Suppl II):II3-II16.
11. Wissler RW. An overview of the quantitative influence of several risk factors on progression of atherosclerosis in young people in the United States. Am J Med Sci 1995; 310(Suppl 1):S29-S36.
12. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 82:657-671.
13. Burke AR Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276-1282.
14. Brown BG, Zhao XQ. Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol 1998; 82:49T-52T.
15. Quyyami AA, Dalak N, Mulcahy D, et al. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol 1997; 29:308-317.
16. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001.
17. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70:1191-1197.
18. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88(5 Pt 1):2149-2155.
19. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334:150-154.
20. Clarkson P. Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28:573-579.
21. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
22. McClellan KJ, Wiseman LR, McTavish D. Cerivastatin. Drugs 1998; 55:415-420.
23. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
24. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.
25. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 1994; 344:1383-1389.
27. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
28. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79:756-762.
29. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
30. Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
31. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341:70-76.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
33. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453-1460.
34. Post Coronary Artery Bypass Graft Trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997; 336:153-162.
35. Gould AL, Rossouw JE, Santanello NC Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97:946-952.
36. Blankenhorn DH, Azen SR Kramsch DM, et al. The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993; 119:969-976.
37. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multi-centre anti-atheroma study (MAAS). Lancet 1994; 344:633-638.
38. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med 1998; 104(Suppl 2A):14S-18S.
39. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2534.
40. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
41. Anderson TJ, Meredith IT, Yeung AC et al. The effect of cholesterol- lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
42. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis 1998; 137:197-203.
43. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 1998; 81:582-587.
44. Vogel RA, Corretti MC Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77:37-40.
45. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
46. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1445.
47. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19:1434-1503.
48. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 19989; 339:229-234.
49. Farmer JA, Gotto Jr AM. Choosing the right lipid-regulating agent. A guide to selection. Drugs 1996; 52:649-661.
50. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678-682.
51. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128-133.
52. Spencer CM, Barradell LB. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidemia. Drugs 1996; 51:982-1018.
53. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation 1993; 87(Suppl II):II-3-II-6.
54. Witztum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996:875-897.
55. Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
56. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81:66B-69B.
57. Crouse JR III, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999; 83:1476-1477.
58. Kastelein JJP, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86:221-223.